Meir Schechter MD, PhDFaculty of Medicine, Hebrew University of Jerusalem, Israel; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel
Meir Schechter is an MD/PhD graduate of the faculty of medicine, Hebrew University of Jerusalem, Israel. He completed his PhD under the mentorship of Prof. Ronit Sharon at the department of biochemistry and molecular biology, investigating molecular mechanisms underlying the pathophysiology of Parkinson’s diseases. His work focused on α-Synuclein interactions with brain lipids, with relevance to neuroplasticity and neurodegeneration.
Meir is now a post-doc fellow at the Diabetes Clinical Research Center at Hadassah Medical Center, Israel, led by Dr. Ofri Mosenzon. His research interests include diabetes and its complications, with specific interests in diabetic kidney disease.
DisclosuresDr. Schechter has no relevant disclosures.
Recent Contributions to PracticeUpdate:
- Effect of Dapagliflozin on the Rate of Decline in Kidney Function in Patients With CKD With and Without T2D
- Effect of Dapagliflozin on Urinary Albumin Excretion in Patients With CKD With and Without T2D
- Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Reduces the Risk of Major Adverse Kidney Events Compared With Other Antihyperglycemics